Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

What was studied

This study looked at exagamglogene autotemcel (exa-cel). It is a one-time gene-edited cell therapy for transfusion-dependent beta-thalassemia. It is approved for ages 12 to 35 years. Earlier, a phase 3 study found transfusion independence. This report looks at later blood and iron measures. They were secondary and exploratory goals of the CLIMB THAL-111 and CLIMB-131 studies. Before treatment, everyone had regular red cell transfusions and iron removal therapy.

What they found

The data cut was April 2025. Of 56 people, 55 had been free of transfusions for 12 months or more. 38 had stopped iron removal therapy. Their mean time off it was 19.4 months. Erythroferrone levels fell. Hepcidin levels returned to normal in all participants. Other red cell markers also improved. These included erythropoietin, reticulocyte counts and soluble transferrin receptor. Iron overload markers fell and then stayed stable. This held even after stopping iron removal therapy.

What it means for patients

The authors say the results show restored red cell production and iron balance after exa-cel. They say this occurred with transfusion independence after fetal hemoglobin reactivation.

Why it is not certain yet

These were secondary and exploratory goals. The abstract gives data up to April 2025. The study had 56 people. The abstract does not give long-term safety results.

Source

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

We restate facts from the source record in our own words. The original wording belongs to its publisher.